awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47574122-153B9EB2-00B3-4492-B0AF-82CA071D2D40
Q47574122-153B9EB2-00B3-4492-B0AF-82CA071D2D40
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47574122-153B9EB2-00B3-4492-B0AF-82CA071D2D40
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
P2860
Q47574122-153B9EB2-00B3-4492-B0AF-82CA071D2D40
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47574122-153B9EB2-00B3-4492-B0AF-82CA071D2D40
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
80800e68fa429de4bda1d1cc28dc3d7ea85f973a
P2860
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).